학술논문

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
Document Type
Article
Source
In The Lancet 29 October-4 November 2016 388(10056):2128-2141
Subject
Primary Research
Articles
Language
ISSN
0140-6736